Temozolomide + radiation treatment improves OS for grade 2 gliomas

ECOG-ACRIN, Caris collaborate on interrogating TAILORx breast cancer trial

ECOG-ACRIN Cancer Research Group and Caris Life Sciences announced a multi-year research collaboration wherein Caris is pairing its genomic, transcriptomic, and proteomic profiling, advanced artificial intelligence and machine learning algorithms with ECOG-ACRIN’s research capabilities.

October 25, 2024

Vol.50 No.40

In Brief

UCLA’s Luca Valle receives $2.1M grant from VA to improve prediction of radiorecurrent prostate cancer outcomes

Luca Valle, assistant professor of radiation oncology at the David Geffen School of Medicine at UCLA, was awarded a $2.1 million grant from the U.S. Department of Veterans Affairs to develop new methods to better understand the clinical scope and biological factors that lead to prostate cancer coming back after radiation therapy.

October 25, 2024

Vol.50 No.40

Clinical

Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer

If clinical research were anything like fly fishing, the scientific question that EA3163 trial attempted to answer might be considered “the one that got away”.

Group chairs propose funding strategy to jump-start correlative studies

The National Academy of Medicine recognized the value of correlative science in publicly funded clinical trials in 2010, recommending “the incorporation of innovative science into cancer clinical trials through the support and use of biorepositories.”

FDA approves Voranigo for grade 2 IDH-mutant glioma

FDA has approved Voranigo (vorasidenib), an isocitrate dehydrogenase-1 and isocitrate dehydrogenase-2 inhibitor, for the treatment of adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.

August 09, 2024

Vol.50 No.32

Drugs & Targets

Expanded access program opens in the U.S. for TLX101-CDx, Telix’s investigational glioma imaging agent

Telix opened an expanded access program in the United States for TLX101-CDx (Pixclara, 18F-floretyrosine or 18F-FET) an investigational positron emission tomography agent for imaging progressive or recurrent glioma, following FDA agreement to proceed.

August 02, 2024

Vol.50 No.31

Temozolomide + radiation treatment improves OS for grade 2 gliomas

YOU MAY BE INTERESTED IN

ECOG-ACRIN, Caris collaborate on interrogating TAILORx breast cancer trial

UCLA’s Luca Valle receives $2.1M grant from VA to improve prediction of radiorecurrent prostate cancer outcomes

Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer

Group chairs propose funding strategy to jump-start correlative studies

FDA approves Voranigo for grade 2 IDH-mutant glioma

Expanded access program opens in the U.S. for TLX101-CDx, Telix’s investigational glioma imaging agent

Renew today!

Subscriber content

Never miss an issue!

Login